Conventional Transarterial Chemoembolization in Single Hepatocellular Carcinoma Less than 5 Cm, Outcome and Overall Survival, Single Center Study

Background: Transarterial chemoembolization (TACE) can be the treatment of choice in patients with single hepatocellular carcinoma (HCC) who aren’t candidates for liver transplantation (LT), local ablation or hepatic resection (HR). Our aim is to determine the efficacy and monitor clinical outcomes in patients with single HCC ≤ 5 cm treated with conventional TACE (cTACE). Method(s): From January 2015 till October 2018, 100 consecutive patients with single HCC ≤ 5 cm underwent cTACE as a first line of treatment. Mean age was 59 years, 56 (56%) were males. Follow up with triphasic CT and AFP was done after 1 month then every 3 months for 3 years. We determined the predictive factors for complete response (CR) and overall survival (OS). Result(s): Seventy-two patients (72%) showed complete response and 28 patients (28%) showed partial response. Superselective TACE and tumor size (< 4 cm) were significant predictor factors for CR (p value < 0.05). The 1- and 3-year overall survival (OS) rates were 90.2% and 70.6% respectively. Complete response (CR) and child class (a) were significant predictive factors for overall survival (OS). Conclusion(s): TACE is an effective treatment in patients with single HCC ≤ 5 cm who aren’t candidate for curative therapy. Super selectivity of TACE and tumor size (< 4 cm) are the predictive factors for complete response (CR). Child class (a) and CR are the predictive factors for overall survival (OS).

Publikationsverlauf

Artikel online veröffentlicht:
11. Mai 2021